IL15 and neoplasm: There are no studies on the therapeutic efficacy of IL-15cx treatment for breast cancer whereas an IL-15 superagonist mutant (IL-15N72D) and dimeric IL-15RαSushi-Fc fusion protein or N803 has been reported to prolong the survival of breast cancer bearing mice with significant antimetastatic activity but no impact on primary tumor growth (24, 25).